Clinical Trials · NCT06373146
A Study of Tirzepatide (LY3298176) Plus Mibavademab Compared With Tirzepatide Alone in Adult Participants With Obesity
- Phase
- Phase 2
- Recruitment status
- Completed
- Sponsor
- Eli Lilly and Company
- Enrollment
- 392
- Start date
- Apr 2024
- Locations
- 17 sites, United States
- Primary endpoint
- Mean Percent Change from Baseline in Body Weight